Current Report Filing (8-k)
November 16 2020 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 16, 2020
JAGUAR HEALTH, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-36714
|
|
46-2956775
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
200 Pine Street, Suite 400
San
Francisco, California
|
|
94104
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (415) 371-8300
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. x
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, Par Value $0.0001 Per Share
|
JAGX
|
The Nasdaq Capital Market
|
Item 2.02 Results of Operations and Financial Conditions
On November 16, 2020, Jaguar Health, Inc. (the “Company”)
issued a press release announcing third quarter 2020 results. A copy of this press release is furnished as Exhibit 99.1 to this
report.
The information in Item 2.02 and the press release furnished
as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, or incorporated by reference
into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
JAGUAR HEALTH, INC.
|
|
|
|
|
|
By:
|
/s/ Lisa A. Conte
|
|
|
Name:
|
Lisa A. Conte
|
|
|
Title:
|
President and Chief Executive Officer
|
Date: November 16, 2020
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Sep 2023 to Sep 2024